文献速递治疗药物监测与药物基因组学特殊人群用药肝肾功能剂量调整

万古霉素首日AUC 400 μg·h/mL的经验剂量测定:一项富采样前瞻性多中心观察研究

Empirical dosage determination of vancomycin for a target area under the concentration-time curve of 400 μg·h/mL in the first 24 h: A prospective multicenter observational study with rich sampling.
PubMed 文献 · Br J Clin Pharmacol · 2025-02-17

该多中心前瞻性观察研究纳入27例危重症患者、共395次采样,评估万古霉素首日AUCf24h>400 μg·h/mL所需经验累积剂量及贝叶斯估计的最佳采样点数。结果显示肌酐清除率>90 mL/min者中AUCf24h>400组首日平均累积剂量49.3 mg/kg高于<400组的42.1 mg/kg(P=0.01),且谷+峰两点采样较单谷浓度改善贝叶斯后验AUC偏差;指南符合剂量组AUCf24h达标概率66.7%显著高于非符合组11.1%(P<0.01)。

要点

  • 首日经验剂量约50 mg/kg可望使AUCf24h>400 μg·h/mL
  • 贝叶斯估计建议采用谷浓度+峰浓度两点采样以提高准确性
  • 按指南剂量给药者AUCf24h达标概率显著更高

核心结论

  • 研究提示万古霉素首日经验剂量约50 mg/kg,并采用两点采样进行贝叶斯估计以提高准确性。

研究设计与样本

  • 多中心前瞻性观察研究,覆盖5家医院,纳入危重症患者27例,共395次采样。
  • 首日和/或治疗第3–5天进行富采样,评估首日梯形AUCf24h及有限采样下AUC与清除率的预测性能。

主要发现

  • 肌酐清除率>90 mL/min患者中,AUCf24h>400 μg·h/mL组首日平均累积剂量(标准差)为49.3(4.5)mg/kg,高于AUCf24h<400组的42.1(6.8)mg/kg(P=0.01)。
  • 仅用谷浓度时贝叶斯后验AUC的偏差和变异,通过采用谷+峰两点浓度得到改善。
  • 指南符合组AUCf24h达标概率为66.7%,显著高于非符合组的11.1%(P<0.01)。

关键数值与推荐

  • 目标AUCf24h>400 μg·h/mL;指南推荐AUCf24h范围为400–600 μg·h/mL。
  • 肌酐清除率>90 mL/min患者首日经验累积剂量约50 mg/kg。
  • 贝叶斯估计采用谷浓度+峰浓度两点采样。

临床怎么用

  • 对肌酐清除率>90 mL/min的危重症患者,首日可考虑约50 mg/kg的经验累积剂量以追求AUCf24h>400 μg·h/mL。
  • 采用贝叶斯估计时优先采集谷浓度与峰浓度两点,以减少后验AUC偏差。
  • 按指南推荐剂量给药可提高AUCf24h落在400–600 μg·h/mL的概率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Area under the concentration-time curve (AUC)-guided dosing is recommended in vancomycin therapy. This study aims to determine the empirical dosing for achieving an AUC on the first day (AUCf24h) and the optimal number of samplings for Bayesian estimation. METHODS: A multicentric prospective study was conducted across five hospitals. Critically ill patients were included, with rich sampling conducted on the first day and/or days 3-5 of therapy. Cumulative dose on the first day for the trapezoidal AUCf24h > 400 μg·h/mL and the predictive performances of AUC and clearance in limited sampling were evaluated. The probability of adherence to AUCf24h within 400-600 μg·h/mL in the guidelines-compliant or non-compliant doses were also evaluated. RESULTS: The study included 27 patients and 395 samplings were performed. The mean cumulative dose (standard deviation) on the first day was higher in the group with AUCf24h > 400 μg·h/mL at 49.3 (4.5) mg/kg compared to the group with AUCf24h < 400 μg·h/mL at 42.1 (6.8) mg/kg (P = 0.01) for patients with creatinine clearance > 90 mL/min, respectively. The biases and variations of Bayesian posterior AUC by using only a trough concentration were improved by using two-point concentrations at trough and peak. The probability of adherence to AUCf24h was significantly higher in the guidelines-compliant group (66.7%) than in the non-compliant group (11.1%, P < .01). CONCLUSION: This study suggested an empirical dosage of about 50 mg/kg on the first day of vancomycin therapy and the use of two-point sampling in Bayesian estimations to enhance accuracy. TRIAL REGISTRATION: Not applicable because this is a non-intervention study.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Oda K, Hiyama Y, Ueda T, et al. Empirical dosage determination of vancomycin for a target area under the concentration-time curve of 400 μg·h/mL in the first 24 h: A prospective multicenter observational study with rich sampling. Br J Clin Pharmacol. 2025. PMID: 39961584. doi:10.1002/bcp.70002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。